Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives

Bibliography

• Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov 2011;6(5):559-87
   PubMed Web of Science ®Google Scholar
• Bio Holding, Inc. Hsp90 inhibitors and methods of use. US20110201587; 2011
   Google Scholar
• Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-35
   PubMed Web of Science ®Google Scholar
• Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010;290:24-35
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271-94
   PubMed Web of Science ®Google Scholar
• Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73
   PubMed Web of Science ®Google Scholar
• Gorska M, Popowska U, Sielicka-Dudzin A, et al. Geldanamycin and its derivatives as Hsp90 inhibitors. Front Biosci 2012;17:2267-77
   Google Scholar
• Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer 2010;10:537-49
   PubMed Web of Science ®Google Scholar
• Porter JR, Ge J, Lee J, et al. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Top Med Chem 2009;9:1386-418
   PubMed Web of Science ®Google Scholar
• DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 1970;23(9):442-7
   PubMedGoogle Scholar
• Erlichman C. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs 2009;18(6):861-8
   PubMed Web of Science ®Google Scholar
• Omura S, Iwai Y, Takakashi Y, et al. Herbimycin A, new antibiotic produced by a strain of Streptomyces. J Antibiot (Tokyo) 1979;32(4):255-61
   PubMedGoogle Scholar
• Tanida S, Hasegawa Y, Higashide E. Macbecins I and II, new antitumor antibiotics. I. Producing organism, fermentation and antimicrobial activities. J Antibiot (Tokyo) 1980;33(2):199-204
   PubMedGoogle Scholar
• Whitesell L, Sutphin P, An WG, et al. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997;14:2809-16
   PubMedGoogle Scholar
• Whitesell L, Mimnaugh EG, Costa BD, et al. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8
   PubMed Web of Science ®Google Scholar
• Kosan Bioscience, Inc. Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor. WO2006119032 A1; 2006
   Google Scholar
• Kim SH, Tangallapally R, Markovitz B, et al. Discovery of (2S) 1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl] 9H purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-Based Hsp90 Inhibitor. J Med Chem 2012;55(17):7480-501
   PubMed Web of Science ®Google Scholar
• Archie NT, David SK, Mithat G, et al. A Phase I dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Caner Res 2008;14:6704-11
   PubMedGoogle Scholar
• Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumor. J Clin Oncol 2005;23:1885-93
   PubMed Web of Science ®Google Scholar
• Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9:1479-4792
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino-17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61
   PubMed Web of Science ®Google Scholar
• Arlander SJ, Eapen AK, Vroman BT, et al. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem 2003;278:52572-7
   PubMed Web of Science ®Google Scholar
• Haluska P, Toft DO, Steinmetz SM, et al. A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. J Clin Oncol (Meeting Abstracts) 2004;22:3058
   Google Scholar
• Richardson PG, Badros AZ, Jagannath S, et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010;150(4):428-37
   PubMedGoogle Scholar
• Tian ZQ, Liu Y, Zhang D, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 2004;12:5317-29
   PubMed Web of Science ®Google Scholar
• Glaze ER, Lambert AL, Smith AC, et al. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005;56:637-47
   PubMed Web of Science ®Google Scholar
• Infinity pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof. US20060019941; 2006
   Google Scholar
• Floris G, Maria DR, Agnieszka W, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther 2011;10(10):1897-908
   PubMed Web of Science ®Google Scholar
• David S, Jagannath S, Vesole DH, et al. A Phase I study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia Lymphoma 2011;52(12):2308-15
   PubMedGoogle Scholar
• Floris G, Raf S, Agnieszha W, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res 2011;17(17):5604-14
   PubMedGoogle Scholar
• Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50
   PubMed Web of Science ®Google Scholar
• Prodromou C, Roe SM, O'Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75
   PubMed Web of Science ®Google Scholar
• Roe SM, Prodromou C, O'Brien R, et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999;42:260-6
   PubMed Web of Science ®Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813-20
   PubMed Web of Science ®Google Scholar
• Edward GM, Chavancy C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271(37):22796-801
   PubMedGoogle Scholar
• De boer Peterson DH. Geldanamycin and process for producing same. US3595995; 1971
   Google Scholar
• University of illinois foundation. Biologically active compounds. US3987035; 1976
   Google Scholar
• Takeda chemical Industries, Ltd. Macbecin derivatives. US4421687; 1983
   Google Scholar
• Takeda chemical Industries, Ltd. Antibiotic TAN-420. US4540517; 1985
   Google Scholar
• Kaken chemical Co., Ltd. Geldanamycin derivatives and antitumor drug. US4261989; 1981
   Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813-20
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Ansamycin derivatives as antioncogene and anticancer agents. US5932566; 1999
   Google Scholar
• Rastelli G, Tian ZQ, Wang Z, et al. Structure-based design of 7-carbamate analogs of geldanamycin. Bioorg Med Chem Lett 2005;15:5016-21
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Bicyclic ansamycins. US5387584; 1995
   Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. erbB-2 Oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813-20
   PubMed Web of Science ®Google Scholar
• Santi D, Myles DC, Tian ZQ, et al. Benzoquinone ansamycins. US20030114450 A1; 2003
   Google Scholar
• Kosan Bioscience, Inc. Benzoquinone ansamycins. US20090111869 A1; 2009
   Google Scholar
• Conforma Therapeutics Corp. Process for preparing 17-allyl amino geldanamycin (17-AAG) and other ansamycins. WO2003026571; 2003
   Google Scholar
• Pfizer, Inc. Process to prepare and isolate geldanamycin. WO2003072794; 2003
   Google Scholar
• Lin Zhang. Ansamycins having improved pharmacological and biological properties. US20050267122 A1; 2005
   Google Scholar
• Conforma Therapeutics Corp. Ansamycins having improved pharmacological and biological properties. US7465718 B2; 2008
   Google Scholar
• Conforma Therapeutics Corp. Compositions containing ansamycin. WO2007064926; 2007
   Google Scholar
• O' Keeffe B, Fong Y, Chen D, et al. Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/Cyclin T1 heterodimer responsible for P-TEFb-mediated Tat stimulation of HIV-1 transcription. J Biol Chem 2000;275(1):279-87
   PubMedGoogle Scholar
• Huezo H, Vilenchik M, Rosen N, Chiosis G. Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chem Biol 2003;10(7):629-34
   PubMedGoogle Scholar
• Abraxis bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof. WO2007059116 A2; 2007
   Google Scholar
• Li LH, Clark TD, Cowie CH, Rinehart KL. Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of rauscher leukemia virus. Cancer Treat Rep 1997;61(5):815-24
   Google Scholar
• Wright JL, Porter JR. Hydroquinone ansamycin formulations. US20080255008 A1; 2008
   Google Scholar
• Schnur RC, Corman ML, Gallaschun RJ, et al. Inhibition of the oncogene product p195(erbB-2) in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38(19):3806-12
   PubMed Web of Science ®Google Scholar
• Kelland LR, Sharp SY, Rogers PM, et al. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, and inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91(22):1940-9
   PubMed Web of Science ®Google Scholar
• Seow HA, Penketh PG, Belcourt MF, et al. Nuclear overexpression of NAD(P)H: quinone oxidoreductase 1 in Chinese hamster ovary cells increase the cytotoxicity of mitomycin C under aerobic and hypoxic condition. J Biol Chem 2004;279(30):31606-12
   PubMedGoogle Scholar
• Ge J, Normant E, Porter JR, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49(15):4606-15
   PubMed Web of Science ®Google Scholar
• Guo W, Reigan P, Siegal D, et al. Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition. Cancer Res 2005;65:10006-15
   PubMed Web of Science ®Google Scholar
• Abraxis bioscience, Inc. Derivatives of 18-amino substituted analogs of the geldanamycin hydroquinone with cytotoxicity activity for the treatment of cancer. WO2008061134; 2008
   Google Scholar
• Institute of medicinal biotechnology academy of medical science. C-19 modified geldanamycin (GDM) derivatives and preparation method thereof. CN102391183; 2012
   Google Scholar
• Institute of medicinal biotechnology academy of medical science. Geldanamycin biosynthetic analogue 19-O-glycyl geldanamycin. CN101792418; 2010
   Google Scholar
• Korea research institute of bioscience and biotechnology. Geldanamycin derivatives by modification of biosynthetic genes. WO2008038877 A1; 2008
   Google Scholar
• Korea research institute of bioscience and biotechnology. Geldanamycin derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and agent for the prevention and treatment of tumor containing the same as an active ingredient. WO2008038964; 2008
   Google Scholar
• Korea research institute of bioscience and biotechnology. Modified microorganisms of geldanamycin biosynthesis regulator genes and the method for producing geldanamycin using the same. KR2010096502; 2010
   Google Scholar
• Korea research institute of bioscience and biotechnology. Cancer prevention and treatment containing the novel geldanamycin derivative, the pharmaceutically acceptable salt thereof, and the manufacturing method thereof and this as active ingredient. KR20120482419; 2012
   Google Scholar
• Institute of medicinal biotechnology, Chinese academy of medical science. Set of geldanamycin derivatives and their preparation methods. US20100311694 A1; 2010
   Google Scholar
• Eichner S, Floss HG, Sasse F, Kirschning A. New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis. Chembiochem 2009;10:1801-5
   PubMedGoogle Scholar
• Knobloch T, Drager G, Collisi W, et al. Unprecedented deoxygeneration at C-7 of the ansamitocin core during mutasynthetic biotransformations. Beilstein J Org Chem 2012;8:861-9
   PubMedGoogle Scholar
• Eichner S, Eichner T, Floss HG, et al. Broad substrate specificity of the amide synthase in S. hygroscopicus – New 20-membered macrolactones derived from geldanamycin. J Am Chem Soc 2012;134:1673-9
   PubMed Web of Science ®Google Scholar
• Takatsu T, Ohtsuki M, Muramatsu A, et al. Reblastatin, a novel benzenoid ansamycin-type cell cycle inhibitor. J Antibiot (Tokyo) 2000;53(11):1310-12
   PubMedGoogle Scholar
• Kosan Biosciences, Inc. Method for treating diseases using Hsp90-inhibiting agents in combination with antimetabolites. WO2005002506; 2005
   Google Scholar
• Kosan Biosciences, Inc. Method for treating diseases using Hsp90-inhibiting agents in combination with antimitotics. WO2005000314; 2005
   Google Scholar
• Kosan Biosciences, Inc. Method for treating diseases using Hsp90-inhibiting agents in combination with antibiotics. WO2005000214; 2005
   Google Scholar
• Kosan Biosciences, Inc. Method for treating diseases using Hsp90-inhibiting agents in combination with immunosuppressants. WO2004108080; 2004
   Google Scholar
• Indian institute of science. Polynucleotide sequence, processes, composition and methods thereof. WO2011154895 A2; 2011
   Google Scholar
• Chroma therapeutics, Ltd. Pyrrolo[2,3-d]pyrimidines as inhibitors of Hsp90. WO2010043867; 2010
   Google Scholar
• Chiang AN, Valderramos JC, Balachandran R, et al. Select pyrimidinones inhibit the propagation of the malarial parasite Plasmodium falciparum. Bioorg Med Chem 2009;17(4):1527-33
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh. Benzoquinone ansamycins for the treatment of cardiac arrest and stroke. US6174875 B1; 2001
   Google Scholar
• Max-planck-gesellschaft zur forderung der wissenschaften ev. Compounds that inhibit Hsp90 and stimulate Hsp70, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation. WO2002094259; 2002
   Google Scholar